<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19218" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Clear Cell Carcinoma of the Cervix</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Limaiem</surname>
            <given-names>Faten</given-names>
          </name>
          <aff>University of Tunis El Manar, Tunis Faculty of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cue</surname>
            <given-names>Lauren</given-names>
          </name>
          <aff>Jersey City Medical Center, Rutgers Barnabas Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Martingano</surname>
            <given-names>Daniel J.</given-names>
          </name>
          <aff>William Carey University; Rutgers University; Episcopal Health Services Inc.</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahdy</surname>
            <given-names>Heba</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Faten Limaiem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lauren Cue declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Martingano declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Heba Mahdy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>4</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19218.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The diagnosis and management of clear cell carcinoma of the cervix is complex, and new approaches are constantly evolving. Clear cell adenocarcinoma of the uterine cervix accounts for only 4% of all adenocarcinoma cases, and about two-thirds are associated with intrauterine diethylstilbestrol (DES) exposure. Nevertheless, cases of clear cell adenocarcinoma have been reported in both adult women and children lacking a history of DES exposure. Compared to adults who suffer from adenocarcinoma, there is a high incidence of stage III and stage IV disease in children and adolescents. The incidence of disease outside of the usual screening age for cervical cancer emphasizes the importance of clinical recognition of the disease so that timely treatment can be delivered. Given the proportion of cases identified in the pediatric and young adult population, fertility-sparing treatment has been emphasized when possible.</p>
        <p>To optimize patient survival, the clinical aspects of clear cell carcinoma of the cervix must be clearly defined, particularly regarding screening, diagnosis, and treatment. This activity describes the epidemiology, predisposing factors, clinical presentation, and management of clear cell carcinoma of the cervix and highlights the role of the interprofessional team in fostering the best possible outcomes for&#x000a0;individuals with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the risk factors for clear cell carcinoma of the cervix.</p></list-item><list-item><p>Assess the clinical presentation of a patient with clear cell adenocarcinoma of the cervix and implement the appropriate diagnostic techniques and imaging modalities necessary for diagnosis.</p></list-item><list-item><p>Differentiate among patients with clear cell carcinoma who are candidates for various current treatment options, including fertility preservation options.</p></list-item><list-item><p>Collaborate with members of an interprofessional team, including gynecologic oncologists, medical oncologists, gynecologists, pediatricians, and family medicine practitioners, to provide efficient, comprehensive, coordinated, and timely care.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19218&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19218">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19218.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Clear cell carcinoma of the uterine cervix is a rare and highly invasive variant of adenocarcinoma and accounts for 4% of all cervical adenocarcinomas.<xref ref-type="bibr" rid="article-19218.r1">[1]</xref>&#x000a0;Although this condition has been historically associated with in-utero exposure to diethylstilbestrol (DES), cases of clear cell adenocarcinoma have been reported in both adult women and children without this exposure.<xref ref-type="bibr" rid="article-19218.r2">[2]</xref> Of note, there is a higher incidence of late-stage (stage III and IV) disease in&#x000a0;the pediatric population when compared to adult patients in whom this condition is diagnosed.<xref ref-type="bibr" rid="article-19218.r3">[3]</xref>&#x000a0;Patients often present to their physician with abnormal vaginal bleeding (premenarchal, intermenstrual, postcoital, postmenopausal), abnormal vaginal discharge, abdominal pain, or lower extremity edema.<xref ref-type="bibr" rid="article-19218.r4">[4]</xref></p>
        <p>The diagnosis of clear cell carcinoma of the uterine cervix is mainly established based on histopathological examination of biopsy-obtained specimens. Histologically, clear cell carcinoma of the uterine cervix is predominantly composed of clear or hobnail cells whose architectural patterns are mixed with solid and tubulocystic patterned areas, mainly composed of nests of cells with clear eosinophilic cytoplasm and hyperchromatic nuclei.<xref ref-type="bibr" rid="article-19218.r5">[5]</xref>&#x000a0;Treatment is dependent upon the stage at diagnosis and patients&#x02019; desires to preserve fertility and can include a combination of surgical, radiation, and chemotherapeutic options.</p>
      </sec>
      <sec id="article-19218.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Historically, clear cell carcinoma of the cervix has been associated with prior intrauterine exposure to DES, a synthetic nonsteroidal estrogen hormone and teratogen with the ability to cross the placenta, although cases have been diagnosed in the absence of exposure.<xref ref-type="bibr" rid="article-19218.r6">[6]</xref> Analysis of molecular mechanisms suggests that DES exposure in utero might lead to a persistent overexpression of protooncogenes that are associated with increased proliferation (c-jun, c-fos, c-myc) or decreased apoptosis (bcl-2, bcl-x), resulting in unregulated cell growth and subsequent carcinogenesis.<xref ref-type="bibr" rid="article-19218.r7">[7]</xref>&#x000a0;Moreover, growth factor genes (such as EGF and TGF-&#x003b1;) have demonstrated overexpression after in utero exposure to DES.<xref ref-type="bibr" rid="article-19218.r8">[8]</xref>&#x000a0;Other estrogen-responsive genes, such as the lactoferrin gene, have been shown to be induced by DES exposure.<xref ref-type="bibr" rid="article-19218.r9">[9]</xref></p>
        <p>The most recent literature suggests that HPV (human papillomavirus) unlikely plays an etiologic role in clear cell carcinoma of the cervix, which sets it apart from most other variants of cervical cancer.<xref ref-type="bibr" rid="article-19218.r10">[10]</xref>&#x000a0;Cervical endometriosis might contribute to the occurrence of clear cell carcinoma of the cervix in women in the absence of DES exposure, given the known association of endometriosis and clear cell carcinoma of the ovary and other sites.<xref ref-type="bibr" rid="article-19218.r11">[11]</xref><xref ref-type="bibr" rid="article-19218.r12">[12]</xref><xref ref-type="bibr" rid="article-19218.r13">[13]</xref>&#x000a0;Overall,&#x000a0;the etiology and pathogenesis of these tumors are not well established, and no clear-cut precursor lesion has been identified, though a few reports suggest that some clear cell carcinomas of the cervix may develop from cervical endometriosis or tubo-endometrioid metaplasia.<xref ref-type="bibr" rid="article-19218.r14">[14]</xref></p>
      </sec>
      <sec id="article-19218.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Clear cell carcinoma of the cervix&#x000a0;is the second most common HPV-independent endocervical adenocarcinomas, representing about 3% of all cases.<xref ref-type="bibr" rid="article-19218.r15">[15]</xref>&#x000a0;A bimodal age distribution has been described in clear cell carcinoma of the cervix, with peaks at 26 years of age (17&#x000a0;to 37) and 71 years of age (44&#x000a0;to 88). DES-exposed patients tend to be younger, with a peak age of 19 years.<xref ref-type="bibr" rid="article-19218.r16">[16]</xref><xref ref-type="bibr" rid="article-19218.r13">[13]</xref></p>
      </sec>
      <sec id="article-19218.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Induction of genomic instability may be an important mechanism of DES-induced carcinogenesis. Somatic mutations of microsatellite repeats have been identified in all DES-associated tumors and 50% of DES-unrelated tumors.<xref ref-type="bibr" rid="article-19218.r17">[17]</xref> Other studies suggest that mutations in the p53 gene, overexpression of the BCL-2 gene, and even cervical endometriosis contribute to the occurrence of clear cell adenocarcinoma.<xref ref-type="bibr" rid="article-19218.r18">[18]</xref><xref ref-type="bibr" rid="article-19218.r19">[19]</xref></p>
      </sec>
      <sec id="article-19218.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Cervical clear cell carcinoma has a similar histologic appearance to clear cell carcinomas found elsewhere in the gynecologic tract, such as the vagina, the endometrium, and the ovary.</p>
        <p>
<bold>Macroscopic Findings&#x000a0;</bold>
</p>
        <p>Clear cell adenocarcinoma of the cervix can appear as a visible exophytic lesion, an endophytic lesion (grossly normal appearing cervix), or a barrel-shaped cervix. On physical examination, lesions can have variable presentations and have presented as everting nodular red lesions or small punctate ulcers.<xref ref-type="bibr" rid="article-19218.r20">[20]</xref>&#x000a0;The average size of a lesion at the time of diagnosis is 3.3 cm.<xref ref-type="bibr" rid="article-19218.r21">[21]</xref></p>
        <p>
<bold>Microscopic Findings&#x000a0;</bold>
</p>
        <p>Clear cell carcinoma of the cervix is characterized microscopically by solid, tubulocystic, and papillary morphology and can&#x000a0;sometimes be admixed within the same tumor. The tumor cells are characterized by abundant clear, glycogen-rich cytoplasm with prominent cell membranes and hyperchromatic nuclei. Clear cell carcinoma can appear as hobnail-type tumor cells and signet ring-type tumor cells.<xref ref-type="bibr" rid="article-19218.r22">[22]</xref>&#x000a0;</p>
        <p>
<bold>Immunohistochemical Studies</bold>
</p>
        <p>The immunohistochemical study is usually noncontributory to the diagnosis of clear cell carcinoma of the uterine cervix. However, it should be noted that CEA stains are negative, which distinguishes it from other types of cervical adenocarcinoma.<xref ref-type="bibr" rid="article-19218.r23">[23]</xref>&#x000a0;Periodic acid-Schiff stains strongly positive in the cytoplasm consistent with glycogen, strongly suggestive of clear cell adenocarcinoma given the glycogen-rich nature of tumor cells.<xref ref-type="bibr" rid="article-19218.r24">[24]</xref>&#x000a0;In a large study comparing clear cell carcinoma of the endometrium and cervix versus the ovary, it was determined that&#x000a0;clear cell carcinomas of the gynecologic tract have a similar spectrum of histopathologic features, with the exception that endometrial clear cell carcinomas have focal solid components more often than clear cell adenocarcinoma of the cervix, and ovarian&#x000a0;clear cell carcinomas, with&#x000a0;endometrial clear cell carcinomas have a slightly higher average mitotic index. Endometrial and cervical clear cell carcinomas were positive for HNF1&#x003b2; and napsin A and rarely expressed estrogen and progesterone, and HNF1&#x003b2; was a sensitive marker for clear cell carcinoma at all 3 sites.<xref ref-type="bibr" rid="article-19218.r25">[25]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-19218.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Clear cell carcinoma of the uterine cervix commonly presents with abnormal vaginal bleeding due to cervical ulceration (postcoital bleeding and/or intermenstrual bleeding). This vaginal bleeding is usually refractory to hormonal therapy.<xref ref-type="bibr" rid="article-19218.r4">[4]</xref></p>
        <p>Physical examination usually depicts a cervical abnormality, often described as a &#x0201c;fullness&#x0201d; of the cervix. The tumor is usually not palpable during the rectal examination.<xref ref-type="bibr" rid="article-19218.r22">[22]</xref></p>
      </sec>
      <sec id="article-19218.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnostic imaging of clear cell carcinoma of the uterine cervix contributes to therapeutic management, surgical planning, and the prediction of prognosis. The main diagnostic modalities utilized in the diagnosis of clear cell carcinoma of the cervix include magnetic resonance (MRI), positron emission tomography/computed tomography (PET/CT), and cytology.</p>
        <p>
<bold>Magnetic Resonance Imaging&#x000a0;</bold>
</p>
        <p>MRI is the method of choice for local-regional tumor staging, evaluation of the treatment response, tumor recurrence detection, and possible complications.<xref ref-type="bibr" rid="article-19218.r26">[26]</xref></p>
        <p>
<bold>F-18 FDG PET/CT&#x000a0;</bold>
</p>
        <p>According to some authors, 18 F-fluorodesoxyglucose&#x02013;positron emission tomography with computed tomography (F-18 FDG PET/CT) can be valuable for evaluating clear cell carcinoma of the uterine cervix with metastatic lymphadenopathy in the pelvic cavity and retroperitoneum.<xref ref-type="bibr" rid="article-19218.r27">[27]</xref></p>
        <p>
<bold>Cytology&#x000a0;</bold>
</p>
        <p>Cytology has been found to be less efficient in diagnosing cervical adenocarcinomas.<xref ref-type="bibr" rid="article-19218.r20">[20]</xref> Some authors reported that only 6 of 31 cervical clear cell carcinoma patients (18%) had an abnormal Pap test. Cytology was of no benefit in the diagnosis.<xref ref-type="bibr" rid="article-19218.r28">[28]</xref></p>
      </sec>
      <sec id="article-19218.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment of clear cell carcinoma is similar to that of cervical cancer, and thus, the prognosis is stage-dependent, although the inherent risk associated with this histology is not well established.<xref ref-type="bibr" rid="article-19218.r29">[29]</xref>&#x000a0;Radical hysterectomy and pelvic lymphadenectomy constitute a standard surgical treatment for patients with&#x000a0;early-stage cervical carcinoma FIGO stage IB or IIA, which results in permanent infertility in the patient.<xref ref-type="bibr" rid="article-19218.r30">[30]</xref>&#x000a0;External beam radiotherapy is the standard of care for stages IIB and IIIB.</p>
        <p>The clinicopathologic findings and prognosis of surgically treated patients with stage IB&#x02013;IIB clear cell carcinomas without exposure to&#x000a0;DES&#x000a0;in utero&#x000a0;are similar to those of patients with squamous cell carcinomas and non-clear cell adenocarcinomas.<xref ref-type="bibr" rid="article-19218.r31">[31]</xref>&#x000a0;</p>
        <p>A recent study revealed oncologic outcomes of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma in young adult women and found no statistically significant survival differences, indicating that for early-stage cancer, fertility-sparing surgery is a safe option.<xref ref-type="bibr" rid="article-19218.r32">[32]</xref></p>
      </sec>
      <sec id="article-19218.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>When evaluating patients with symptoms suggestive of clear cell carcinoma of the cervix, it is essential to consider differential diagnoses that may present similarly, such as cervical squamous cell carcinoma, other cervical adenocarcinoma, benign cervical lesions, or infections like cervicitis. Discriminating between these conditions is crucial for accurate diagnosis and appropriate management. Differential diagnoses include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Metastatic clear cell carcinoma from other sites</p>
          </list-item>
          <list-item>
            <p>Arias-Stella reaction</p>
          </list-item>
          <list-item>
            <p>Adenosis</p>
          </list-item>
          <list-item>
            <p>Endometrioid adenocarcinoma with clear cell or secretory change</p>
          </list-item>
          <list-item>
            <p>Gastric-type of endocervical adenocarcinoma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cervical yolk sac tumors</p>
          </list-item>
          <list-item>
            <p>Primary cervical alveolar soft part sarcomas</p>
          </list-item>
          <list-item>
            <p>Benign cervical lesions</p>
          </list-item>
          <list-item>
            <p>Cervicitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19218.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>
<bold>Fertility Preserving Surgery</bold>
</p>
        <p>Upon diagnosis with clear cell adenocarcinoma of the cervix, women of reproductive age usually desire to preserve their fertility. However, only the histological characteristics of squamous cell carcinoma, adenocarcinoma, or&#x000a0;adenosquamous carcinoma are incorporated into the widely accepted criteria for radical trachelectomy.<xref ref-type="bibr" rid="article-19218.r4">[4]</xref>&#x000a0;Clear cell adenocarcinoma is generally considered an aggressive subtype, and fertility-sparing surgery is only recently being considered and explored in this subtype.<xref ref-type="bibr" rid="article-19218.r33">[33]</xref>&#x000a0;In most recent studies, fertility preservation surgery has been offered to those with stage IA&#x02013;IB disease. In a retrospective study by Liu et al, no recurrence or death was detected, and the obstetric outcomes were quite favorable, with a pregnancy rate of 100%, a live birth rate of 100%, and a preterm birth rate of 50%.<xref ref-type="bibr" rid="article-19218.r4">[4]</xref> This suggests that fertility-sparing treatment in reproductive-aged patients with early-stage clear cell carcinoma of the cervix could be safe and feasible and eventually become more widely practiced. Nevertheless, it is currently recommended by the lead investigators in these studies that fertility preservation be offered prudently because of the currently limited but growing knowledge on this issue.</p>
      </sec>
      <sec id="article-19218.s12" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Weekly cisplatin plus radiotherapy is the standard regimen for advanced cervical cancer.<xref ref-type="bibr" rid="article-19218.r4">[4]</xref>&#x000a0;Previous studies have evaluated whether platinum-based doublet therapy improves survival compared to weekly cisplatin plus radiotherapy. Lee et al reported that in cervical cancer with pelvic lymph node metastasis, platinum-based polychemotherapy as combination chemotherapy conferred favorable survival compared to weekly cisplatin, reducing the risk of recurrence by 77%.<xref ref-type="bibr" rid="article-19218.r34">[34]</xref> A systematic review supported that in patients with locally advanced cervical cancer who underwent chemoradiotherapy, cisplatin-based doublets had improved overall survival, progression-free survival, and local control in comparison with concomitant cisplatin chemotherapy.<xref ref-type="bibr" rid="article-19218.r35">[35]</xref> The goal is for this combined therapy to lead to increased cytotoxicity and radiosensitization compared to cisplatin as a single agent. Since adenocarcinoma of the cervix is not as radiosensitive as squamous cell carcinoma, clear cell adenocarcinoma of the cervix, as a subtype of adenocarcinoma, may best be treated with platinum-based doublet therapy plus radiotherapy.<xref ref-type="bibr" rid="article-19218.r36">[36]</xref></p>
      </sec>
      <sec id="article-19218.s13" sec-type="Staging">
        <title>Staging</title>
        <p>Staging according to the new International Federation of Gynecology and Obstetrics (FIGO) classification is as follows:&#x000a0;<xref ref-type="bibr" rid="article-19218.r26">[26]</xref></p>
        <p>
<bold>Stage 1</bold>
</p>
        <p>The tumor is limited to the cervix.&#x000a0;</p>
        <p>
<bold>Stage 1A</bold>
</p>
        <p>Microinvasive carcinoma limited to the cervix that is only microscopically visible. The maximum invasion depth is &#x0003c;5 mm.</p>
        <p>1A1 stromal invasion &#x0003c;3 mm</p>
        <p>1A2 stromal invasion &#x02265;3 mm and &#x02264;5 mm</p>
        <p>
<bold>Stage 1B</bold>
</p>
        <p>Invasive carcinoma limited to the cervix with stromal invasion of &#x02265;5 mm or a clinically visible tumor</p>
        <p>1B1 clinically visible tumor &#x0003c;2 cm or microscopically visible lesion with an invasion depth of &#x02265;5 mm</p>
        <p>1B2 invasive carcinoma with a diameter of &#x02265;2 cm and &#x02264;4 cm</p>
        <p>1B3 invasive carcinoma with a diameter of &#x02265;4 cm</p>
        <p>
<bold>Stage 2</bold>
</p>
        <p>The tumor is not limited to the cervix and infiltrates the upper 2/3 of the vagina or the parametria.&#x000a0;</p>
        <p>
<bold>Stage 2A</bold>
</p>
        <p>Infiltration of the upper 2/3 of the vagina</p>
        <p>
<bold>Stage 2B</bold>
</p>
        <p>Infiltration of the parametria but the pelvic wall is not affected</p>
        <p>
<bold>Stage 3</bold>
</p>
        <p>Infiltration of the lower 1/3 of the vagina or the pelvic wall</p>
        <p>
<bold>Stage 3A</bold>
</p>
        <p>Tumor extends to the lower 1/3 of the vagina but does not reach the pelvic wall</p>
        <p>
<bold>Stage 3B</bold>
</p>
        <p>Infiltration of the pelvic wall or the ureters resulting in hydronephrosis. Per definition, pelvic wall infiltration is present when the iliac vessels, the obturator internus muscle, the piriformis muscle, or the levator ani muscle is infiltrated.</p>
        <p>
<bold>Stage 3C</bold>
</p>
        <p>Pelvic and/or retroperitoneal lymph node metastases, regardless of tumor size or extent</p>
        <p>3C1 pelvic lymph node metastases</p>
        <p>3C2 retroperitoneal lymph node metastases in the TNM classification; the involvement of retroperitoneal lymph nodes is categorized as distant metastasis (M1).</p>
        <p>
<bold>Stage 4</bold>
</p>
        <p>Detection of infiltration of the bladder and/or rectum or extension of the tumor beyond the borders of the small pelvis</p>
        <p>
<bold>Stage 4A</bold>
</p>
        <p>Infiltration of the bladder and/or rectum to the mucosa&#x000a0;</p>
        <p>
<bold>Stage 4B</bold>
</p>
        <p>Presence of distant metastases</p>
      </sec>
      <sec id="article-19218.s14" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Studies regarding prognosis are conflicting; some report equivalent outcomes with conventional cervical adenocarcinoma, whereas others report a much more aggressive disease course.<xref ref-type="bibr" rid="article-19218.r33">[33]</xref></p>
        <p>Important parameters for the determination of prognosis of cervical clear cell carcinoma include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>FIGO stage</p>
          </list-item>
          <list-item>
            <p>Tumor size</p>
          </list-item>
          <list-item>
            <p>Growth pattern</p>
          </list-item>
          <list-item>
            <p>Nuclear atypia</p>
          </list-item>
          <list-item>
            <p>Mitotic activity</p>
          </list-item>
          <list-item>
            <p>Depth of stromal invasion</p>
          </list-item>
        </list>
        <p>The most significant prognostic factors for progression-free survival and overall survival among those above are the FIGO stage and pelvic node status.<xref ref-type="bibr" rid="article-19218.r37">[37]</xref></p>
        <p>There are no published data on the differences in prognosis between clear cell carcinoma and gastric type endocervical adenocarcinoma subtype and between clear cell carcinoma and HPV-associated cervical adenocarcinoma. Other than case reports demonstrating that&#x000a0;clear cell carcinomas have a worse prognosis than HPV-associated cervical adenocarcinoma, the&#x000a0;2 largest studies did not correlate&#x000a0;clear cell carcinoma survival with those of HPV-associated cervical adenocarcinoma and/or with gastric-type cervical adenocarcinoma since these studies were performed before the introduction of the etiology-based classification system.<xref ref-type="bibr" rid="article-19218.r38">[38]</xref><xref ref-type="bibr" rid="article-19218.r21">[21]</xref></p>
        <p>Another larger study comparing treatment prognosis for clear cell carcinoma versus&#x000a0;gastric-type endocervical adenocarcinoma subtype noted that clear cell carcinomas have poorer outcomes than HPV-associated endocervical adenocarcinomas and similar outcomes to HPV-independent gastric-type adenocarcinoma, but are stage dependent.<xref ref-type="bibr" rid="article-19218.r14">[14]</xref><xref ref-type="bibr" rid="article-19218.r38">[38]</xref></p>
      </sec>
      <sec id="article-19218.s15" sec-type="Complications">
        <title>Complications</title>
        <p>Most studies concur that clear cell carcinoma is a tumor associated with lymphovascular space invasion and lymph node metastases, with pelvic lymph node involvement noted in as high as 25% of cases.<xref ref-type="bibr" rid="article-19218.r38">[38]</xref>&#x000a0;Similarly, Stolnicu et al, found lymphovascular invasion in 31% and lymph node metastases in 24.1%.<xref ref-type="bibr" rid="article-19218.r14">[14]</xref> In addition, 10.3% were associated with abdomino-pelvic metastases, 32.8% had recurrences and 19% died of disease.<xref ref-type="bibr" rid="article-19218.r14">[14]</xref>&#x000a0;</p>
        <p>The sites of recurrence included the following: lung, liver, bone, brain, peritoneum, retroperitoneum, mediastinal lymph nodes, vagina and sigmoid colon.<xref ref-type="bibr" rid="article-19218.r39">[39]</xref>&#x000a0;Most recurrences of clear cell carcinoma of the uterine cervix&#x000a0;are diagnosed within&#x000a0;3 years after primary tumor treatment.<xref ref-type="bibr" rid="article-19218.r32">[32]</xref>&#x000a0;However, late recurrences have been reported with a few cases,&#x000a0;8 years after initial diagnosis.<xref ref-type="bibr" rid="article-19218.r40">[40]</xref>&#x000a0;High-risk factors for recurrence include positive parametrial extension, positive pelvic lymph nodes, and positive vaginal margins. In patients with these high-risk factors, chemoradiation is the postoperative adjuvant treatment of choice.<xref ref-type="bibr" rid="article-19218.r37">[37]</xref></p>
      </sec>
      <sec id="article-19218.s16" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultations are pivotal in the comprehensive care of patients diagnosed with clear cell carcinoma of the cervix, ensuring multidisciplinary collaboration and tailored management. Appropriate consultations may include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gynecologist</p>
          </list-item>
          <list-item>
            <p>Surgical/ Gynecologic oncologist</p>
          </list-item>
          <list-item>
            <p>Medical oncologist</p>
          </list-item>
          <list-item>
            <p>Radiation oncologist</p>
          </list-item>
          <list-item>
            <p>Pathologist</p>
          </list-item>
          <list-item>
            <p>Reproductive endocrinologist</p>
          </list-item>
          <list-item>
            <p>Pharmacy oncology specialist</p>
          </list-item>
          <list-item>
            <p>Oncology nurse</p>
          </list-item>
          <list-item>
            <p>Palliative care specialist</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19218.s17" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Deterrence and prevention of clear cell carcinoma of the cervix primarily hinge on addressing modifiable risk factors and promoting regular screening practices. Education on avoiding exposure to known carcinogens, such as DES, during pregnancy is crucial.</p>
        <p>The care providers should ensure that patients are instructed to immediately consult their providers if they develop any symptoms of abnormal uterine bleeding.&#x000a0;Particular attention should be paid to instances of premenarchal, postmenopausal, and intermenstrual bleeding. These symptoms warrant immediate attention from a healthcare provider who should have a low threshold to biopsy any suspicious lesions identified on physical examination.&#x000a0;</p>
        <p>The interprofessional team should ensure that patients are provided&#x000a0;with written information or referred to educational websites to help patients better understand the nature of their condition, including its etiology, symptoms, diagnostic procedures, treatment options, potential&#x000a0;adverse effects, and prognosis. Additionally, resources on coping mechanisms, support groups, and avenues for further information should be offered to empower patients in managing their disease and making informed decisions regarding their care.</p>
      </sec>
      <sec id="article-19218.s18" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>
<bold>Screening</bold>
</p>
        <p>Women whose mothers took DES during pregnancy must undergo regular gynecologic exams throughout their lifetimes. These women should receive a cytological screening twice yearly until the age of 60 years.<xref ref-type="bibr" rid="article-19218.r41">[41]</xref> DES-exposed women should receive a pelvic exam, pap smears of the cervix and vagina, and colposcopy.<xref ref-type="bibr" rid="article-19218.r42">[42]</xref> The cervical Papanicolaou test may not be adequate for DES-exposed daughters. Therefore, the cervical Papanicolaou test must be supplemented with a Papanicolaou test of the vagina, known as the &#x0201c;four-quadrant&#x0201d; Papanicolaou test, which samples all sides of the upper vagina.&#x000a0;Cervical and vaginal palpation of an irregular mass may initiate the workup that ultimately leads to a diagnosis of clear cell carcinoma of the cervix.<xref ref-type="bibr" rid="article-19218.r43">[43]</xref></p>
        <p>
<bold>Possible correlation with genitourinary malformations such as Mullerian anomalies</bold>
</p>
        <p>It has been reported that the prevalence of congenital malformations in cervical or vaginal clear cell carcinoma was 6%.<xref ref-type="bibr" rid="article-19218.r44">[44]</xref>&#x000a0;Additional studies have reported that 69% of the patients with genitourinary malformations had adenocarcinoma of the lower genital tract.<xref ref-type="bibr" rid="article-19218.r45">[45]</xref>&#x000a0;This raises the possibility that congenital anomalies are linked to an elevated risk of primary malignancies. The M&#x000fc;llerian epithelium, according to a theory by Sporri et al, may become vulnerable to carcinogenic substances due to teratogenic effects.<xref ref-type="bibr" rid="article-19218.r46">[46]</xref>&#x000a0;Direct causation at a genetic level has not been proven; however, it is recommended that in individuals with genitourinary abnormalities, it is necessary to determine their genetic profile and probability of developing cancer.<xref ref-type="bibr" rid="article-19218.r4">[4]</xref></p>
      </sec>
      <sec id="article-19218.s19" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Successful management of clear cell carcinoma of the cervix requires an interprofessional approach involving a team that consists of a gynecologic oncologist, a medical oncologist, a radiation oncologist, a pathologist, and a radiologist with expertise in pelvic anatomy. Following successful treatment of clear cell carcinoma of the cervix, long-term&#x000a0;follow-up over years is necessary to detect local and distant recurrences.&#x000a0;The primary care provider and nurse practitioner must refer patients with any abnormal uterine bleeding to a gynecologist for further workup. Similarly, a gynecologist must refer patients to a gynecologic oncologist once a tissue sample is obtained, conferring the diagnosis of malignancy.</p>
        <p>All healthcare professionals who care for female patients at various stages of their lives must be familiar with the presenting symptoms, diagnostic methods, and treatment of clear cell carcinoma of the cervix to reduce delays in care and subsequent advancement of disease and worsening of prognosis. Healthcare providers should also be aware of the incidence of clear cell carcinoma of the uterine cervix in children and adolescents and be able to refer to a tertiary gynecological oncology center promptly.</p>
        <p>An interprofessional clinical team should collaborate and communicate amongst themselves and with the patient to obtain the best results. The oncology specialty nurse should assist with patient and family education and arrange coordination between the specialists. A pharmacist plays a crucial role throughout the management of oncology patients and should assist with pain management while providing guidance regarding drug interactions and patient tolerance of&#x000a0;adverse effects, as well as performing overall medication reconciliation and reporting to the healthcare team any concerns they encounter. A palliative care specialist should be available to help patients cope emotionally and clarify goals of care throughout the course of treatment and as the prognosis evolves. Ideal outcomes for those who have received a diagnosis of clear cell carcinoma of the cervix are only obtainable amidst collaboration among interprofessional team members and with guided shared decision-making in conjunction with the patient and her family.&#x000a0;</p>
      </sec>
      <sec id="article-19218.s20">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19218&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19218">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/womens-health/clear-cell-carcinoma-of-the-cervix/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19218">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19218/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19218">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19218.s21">
        <title>References</title>
        <ref id="article-19218.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bujor</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Lozneanu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ursache</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cristofor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scurtu</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Plamadeala</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gireada</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mandici</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>G&#x00103;in&#x00103;</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Matasariu</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Primary Clear Cell Adenocarcinoma of the Uterine Cervix in a 14-Year-Old Virgin Girl: Case Report.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2022</year>
            <month>Dec</month>
            <day>11</day>
            <volume>19</volume>
            <issue>24</issue>
            <pub-id pub-id-type="pmid">36554533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herbst</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Ulfelder</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Poskanzer</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women.</article-title>
            <source>N Engl J Med</source>
            <year>1971</year>
            <month>Apr</month>
            <day>22</day>
            <volume>284</volume>
            <issue>15</issue>
            <fpage>878</fpage>
            <page-range>878-81</page-range>
            <pub-id pub-id-type="pmid">5549830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teixeira</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Vale</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Bragan&#x000e7;a</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Zeferino</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Cervical cancer in women under 25&#x000a0;years of age and outside the screening age: Diagnosis profile and long-term outcomes.</article-title>
            <source>Int J Gynaecol Obstet</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>154</volume>
            <issue>1</issue>
            <fpage>150</fpage>
            <page-range>150-156</page-range>
            <pub-id pub-id-type="pmid">33341962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Clinical Features and Prognostic Factors of Cervical Clear Cell Adenocarcinoma: A Retrospective Analysis of 74 Cases from a Tertiary Hospital.</article-title>
            <source>Technol Cancer Res Treat</source>
            <year>2023</year>
            <season>Jan-Dec</season>
            <volume>22</volume>
            <fpage>15330338221149297</fpage>
            <pub-id pub-id-type="pmid">36718531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Secosan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Balint</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ilian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Balan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Balulescu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Motoc</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zahoi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Grigoras</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pirtea</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>New Insights in the Diagnosis of Rare Adenocarcinoma Variants of the Cervix-Case Report and Review of Literature.</article-title>
            <source>Healthcare (Basel)</source>
            <year>2022</year>
            <month>Jul</month>
            <day>28</day>
            <volume>10</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">36011067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Herbst</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up.</article-title>
            <source>Gynecol Oncol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>146</volume>
            <issue>3</issue>
            <fpage>566</fpage>
            <page-range>566-571</page-range>
            <pub-id pub-id-type="pmid">28689666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verloop</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van Leeuwen</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Helmerhorst</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>van Boven</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Rookus</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Cancer risk in DES daughters.</article-title>
            <source>Cancer Causes Control</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>999</fpage>
            <page-range>999-1007</page-range>
            <pub-id pub-id-type="pmid">20204493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fukazawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Iguchi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Involvement of growth factors in induction of persistent proliferation of vaginal epithelium of mice exposed neonatally to diethylstilbestrol.</article-title>
            <source>Reprod Toxicol</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-51</page-range>
            <pub-id pub-id-type="pmid">15336711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newbold</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Padilla-Banks</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jefferson</surname>
                <given-names>WN</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of the model environmental estrogen diethylstilbestrol are transmitted to subsequent generations.</article-title>
            <source>Endocrinology</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>147</volume>
            <issue>6 Suppl</issue>
            <fpage>S11</fpage>
            <page-range>S11-7</page-range>
            <pub-id pub-id-type="pmid">16690809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stolnicu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Soslow</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in invasive adenocarcinoma of the cervix.</article-title>
            <source>Virchows Arch</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>475</volume>
            <issue>5</issue>
            <fpage>537</fpage>
            <page-range>537-549</page-range>
            <pub-id pub-id-type="pmid">31209635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMullan</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>McCluggage</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Feeney</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The malignant transformation of endometriosis: Is there a left lateral predisposition of ovarian clear cell and endometrioid carcinomas?</article-title>
            <source>Eur J Surg Oncol</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>108247</fpage>
            <pub-id pub-id-type="pmid">38522332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Arora</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mullangi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vadakekut</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Lekkala</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <chapter-title>Epithelial Ovarian Cancer</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">33620837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Younis</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Izhaki</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>At what age endometriosis-associated ovarian cancer is diagnosed? The implications for women in the reproductive age.</article-title>
            <source>Front Oncol</source>
            <year>2023</year>
            <volume>13</volume>
            <fpage>1193123</fpage>
            <pub-id pub-id-type="pmid">37287920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stolnicu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karpathiou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guerra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mateoiu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reques</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Felix</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fanni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gama</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hardisson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Parra-Herran</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oliva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abu-Rustum</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Soslow</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Clear Cell Carcinoma (CCC) of the Cervix Is a Human Papillomavirus (HPV)-independent Tumor Associated With Poor Outcome: A Comprehensive Analysis of 58 Cases.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2022</year>
            <month>Jun</month>
            <day>01</day>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>765</fpage>
            <page-range>765-773</page-range>
            <pub-id pub-id-type="pmid">34985047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stolnicu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barsan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Terinte</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pesci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aviel-Ronen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kiyokawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Alvarado-Cabrero</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pike</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Oliva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Soslow</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>214</fpage>
            <page-range>214-226</page-range>
            <pub-id pub-id-type="pmid">29135516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herbst</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Behavior of estrogen-associated female genital tract cancer and its relation to neoplasia following intrauterine exposure to diethylstilbestrol (DES).</article-title>
            <source>Gynecol Oncol</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>76</volume>
            <issue>2</issue>
            <fpage>147</fpage>
            <page-range>147-56</page-range>
            <pub-id pub-id-type="pmid">10637063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Waggoner</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Hajek</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wharton</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Fujino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero.</article-title>
            <source>Cancer</source>
            <year>1996</year>
            <month>Feb</month>
            <day>01</day>
            <volume>77</volume>
            <issue>3</issue>
            <fpage>507</fpage>
            <page-range>507-13</page-range>
            <pub-id pub-id-type="pmid">8630958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bocaneti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Altamura</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corteggio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Velescu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Borzacchiello</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Expression of bcl-2 and p53 in bovine cutaneous fibropapillomas.</article-title>
            <source>Infect Agent Cancer</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <pub-id pub-id-type="pmid">25601891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakayama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Minamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishibashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohnishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sasamori</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Razia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hossain</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kamrunnahar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kyo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Lynch Syndrome-Related Clear Cell Carcinoma of the Cervix: A Case Report.</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>Mar</month>
            <day>25</day>
            <volume>19</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">29587389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>LY</given-names>
              </name>
            </person-group>
            <article-title>Clear cell carcinoma of the uterine cervix: clinical characteristics and feasibility of fertility-preserving treatment.</article-title>
            <source>Onco Targets Ther</source>
            <year>2014</year>
            <volume>7</volume>
            <fpage>111</fpage>
            <page-range>111-6</page-range>
            <pub-id pub-id-type="pmid">24470762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Clear Cell Carcinoma of the Uterine Cervix: A Clinical and Pathological Analysis of 47 Patients Without Intrauterine Diethylstilbestrol Exposure.</article-title>
            <source>Int J Gynecol Cancer</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>1009</fpage>
            <page-range>1009-1014</page-range>
            <pub-id pub-id-type="pmid">28498261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Herbst</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Follow-up of Patients with Clear-Cell Adenocarcinoma of the Vagina and Cervix.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>May</month>
            <day>03</day>
            <volume>378</volume>
            <issue>18</issue>
            <fpage>1746</fpage>
            <page-range>1746-1748</page-range>
            <pub-id pub-id-type="pmid">29719188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Kiyokawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Soslow</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Lamb</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Oliva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zivanovic</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Juretzka</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Pirog</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2011</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>633</fpage>
            <page-range>633-46</page-range>
            <pub-id pub-id-type="pmid">21490443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathew Thomas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hadfield</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vredenburgh</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A Rare Case of Clear Cell Adenocarcinoma of the Cervix with No Intrauterine Diethylstilbestrol Exposure.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Apr</month>
            <day>23</day>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>e7796</fpage>
            <pub-id pub-id-type="pmid">32461864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ju</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Morphologic and Immunohistochemical Study of Clear Cell Carcinoma of the Uterine Endometrium and Cervix in Comparison to Ovarian Clear Cell Carcinoma.</article-title>
            <source>Int J Gynecol Pathol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>388</fpage>
            <page-range>388-396</page-range>
            <pub-id pub-id-type="pmid">28796747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bossart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bamberg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eisenblaetter</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Revised FIGO Staging for Cervical Cancer - A New Role for MRI.</article-title>
            <source>Rofo</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>192</volume>
            <issue>10</issue>
            <fpage>937</fpage>
            <page-range>937-944</page-range>
            <pub-id pub-id-type="pmid">32731266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mutic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Grigsby</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2006</year>
            <month>May</month>
            <day>01</day>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>177</fpage>
            <page-range>177-81</page-range>
            <pub-id pub-id-type="pmid">16545921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tantitamit</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hamontri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rangsiratanakul</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clear cell adenocarcinoma of the cervix in second generation young women who are without maternal exposure to diethylstilbestrol: A case report.</article-title>
            <source>Gynecol Oncol Rep</source>
            <year>2017</year>
            <month>May</month>
            <volume>20</volume>
            <fpage>34</fpage>
            <page-range>34-36</page-range>
            <pub-id pub-id-type="pmid">28275694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Eom</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic assessments and treatment results of well-differentiated gastric-type adenocarcinoma of the uterine cervix (Adenoma malignum): A multicenter retrospective analysis of KROG 22-03 study.</article-title>
            <source>Gynecol Oncol</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>182</volume>
            <fpage>45</fpage>
            <page-range>45-50</page-range>
            <pub-id pub-id-type="pmid">38246046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Primary Clear Cell Adenocarcinoma of the Cervix: A Clinical Analysis of 18 Cases without Exposure to Diethylstilbestrol.</article-title>
            <source>Obstet Gynecol Int</source>
            <year>2019</year>
            <volume>2019</volume>
            <fpage>9465375</fpage>
            <pub-id pub-id-type="pmid">31049066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reich</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Tamussino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lahousen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pickel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clear cell carcinoma of the uterine cervix: pathology and prognosis in surgically treated stage IB-IIB disease in women not exposed in utero to diethylstilbestrol.</article-title>
            <source>Gynecol Oncol</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>331</fpage>
            <page-range>331-5</page-range>
            <pub-id pub-id-type="pmid">10684706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diaz</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Sonoda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Leitao</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Zivanovic</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Barakat</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Abu-Rustum</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma.</article-title>
            <source>Gynecol Oncol</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>111</volume>
            <issue>2</issue>
            <fpage>255</fpage>
            <page-range>255-60</page-range>
            <pub-id pub-id-type="pmid">18755500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Machida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okugawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morishige</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yoshino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tokunaga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shozu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yaegashi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Enomoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mikami</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fertility-sparing trachelectomy for early-stage cervical cancer: A proposal of an ideal candidate.</article-title>
            <source>Gynecol Oncol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>156</volume>
            <issue>2</issue>
            <fpage>341</fpage>
            <page-range>341-348</page-range>
            <pub-id pub-id-type="pmid">31767188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis.</article-title>
            <source>Anticancer Res</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>4675</fpage>
            <page-range>4675-81</page-range>
            <pub-id pub-id-type="pmid">24123048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petrelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Stefani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raspagliesi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lorusso</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barni</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis.</article-title>
            <source>Gynecol Oncol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>134</volume>
            <issue>1</issue>
            <fpage>166</fpage>
            <page-range>166-71</page-range>
            <pub-id pub-id-type="pmid">24793000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2012</year>
            <month>Oct</month>
            <day>01</day>
            <volume>84</volume>
            <issue>2</issue>
            <fpage>420</fpage>
            <page-range>420-7</page-range>
            <pub-id pub-id-type="pmid">22365621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clear Cell Adenocarcinoma of Uterine Cervix: A Single Institution Retrospective Experience.</article-title>
            <source>Front Oncol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>532748</fpage>
            <pub-id pub-id-type="pmid">33282724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Leiser</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Mutch</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Podratz</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Dowdy</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era.</article-title>
            <source>Gynecol Oncol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>109</volume>
            <issue>3</issue>
            <fpage>335</fpage>
            <page-range>335-9</page-range>
            <pub-id pub-id-type="pmid">18394687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pors</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Segura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Almadani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fix</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Howitt</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Kolin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McCluggage</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Mirkovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gilks</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract: A Multi-institutional Study.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>498</fpage>
            <page-range>498-506</page-range>
            <pub-id pub-id-type="pmid">33165093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Koulos</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Saigo</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Clear-cell adenocarcinoma of the lower genital tract: Memorial Hospital 1974-1984.</article-title>
            <source>Obstet Gynecol</source>
            <year>1987</year>
            <month>Oct</month>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>573</fpage>
            <page-range>573-7</page-range>
            <pub-id pub-id-type="pmid">3627626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verheijen</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Verloop</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Helmerhorst</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>[DES Daughter--expertise remains necessary].</article-title>
            <source>Ned Tijdschr Geneeskd</source>
            <year>2013</year>
            <volume>157</volume>
            <issue>52</issue>
            <fpage>A6809</fpage>
            <pub-id pub-id-type="pmid">24382040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camp</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Prehn</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Herbst</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Strohsnitter</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Hobday</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Robboy</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Factors associated with a lack of pap smear utilization in women exposed in utero to diethylstilbestrol.</article-title>
            <source>J Womens Health (Larchmt)</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>308</fpage>
            <page-range>308-15</page-range>
            <pub-id pub-id-type="pmid">25768943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Laitman</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Diethylstilbestrol (DES) update: recommendations for the identification and management of DES-exposed individuals.</article-title>
            <source>J Midwifery Womens Health</source>
            <year>2003</year>
            <season>Jan-Feb</season>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-29</page-range>
            <pub-id pub-id-type="pmid">12589302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herbst</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Robboy</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Scully</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Poskanzer</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Clear-cell adenocarcinoma of the vagina and cervix in girls: analysis of 170 registry cases.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>1974</year>
            <month>Jul</month>
            <day>01</day>
            <volume>119</volume>
            <issue>5</issue>
            <fpage>713</fpage>
            <page-range>713-24</page-range>
            <pub-id pub-id-type="pmid">4857957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Carcinoma of the lower female genital tract in patients with genitourinary malformations: a clinicopathologic analysis of 36 cases.</article-title>
            <source>J Cancer</source>
            <year>2019</year>
            <volume>10</volume>
            <issue>13</issue>
            <fpage>3054</fpage>
            <page-range>3054-3061</page-range>
            <pub-id pub-id-type="pmid">31281483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19218.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sp&#x000f6;rri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Altermatt</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Dreher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>H&#x000e4;nggi</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Clear cell adenocarcinoma of the cervix associated with a rare genitourinary malformation.</article-title>
            <source>Obstet Gynecol</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>96</volume>
            <issue>5 Pt 2</issue>
            <fpage>834</fpage>
            <page-range>834-6</page-range>
            <pub-id pub-id-type="pmid">11094228</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
